Hormones in the treatment of metastatic renal cancer.
Metastatic renal adenocarcinoma has been highly resistant to most therapeutic approaches. However, hormonal treatment has been reported to induce significant subjective or objective improvement. Two groups of patients receiving either androgens or progestogens were evaluated. The number of responses was disappointing. Furthermore, neither of the 2 regimens appeared to increase the mean surival between detection of metastases and fatal outcome.
D000230:Adenocarcinoma / Q000188:drug therapy*; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D009362:Neoplasm Metastasis
D005474:Fluoxymesterone; D008525:Medroxyprogesterone